AzTrials
AzTrials

TracheobronchomalaciaNCT04169282

PEEP Mask for Tracheobronchomalacia-Induced Cough

A study testing nPEP (non-invasive positive expiratory pressure) mask in people with Tracheobronchomalacia, run by Duke University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to determine if an expiratory resistance device that delivers non-invasive positive expiratory pressure (nPEP) will reduce or stop coughing, reduce airway resistance and improve quality of life in patients with tracheobronchomalacia (TBM) who are not candidates for tracheal stenting. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Tracheobronchomalacia
What is being tested?
nPEP (non-invasive positive expiratory pressure) mask
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
30 Aug 2021to 15 Aug 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Visualization of ≥50% collapse of the trachea or mainstem bronchus on CT scan or bronchoscopy
  • No upper or lower respiratory infection within 4 weeks
  • Having capacity to provide legal written informed consent

Who cannot join

  • History of tracheobronchoplasty or chronic tracheal stenting
  • Current tracheostomy
  • History of external chest trauma
  • History of:
  • Active treatment for Lung cancer
  • Lung transplantation
Show all 10Show fewer
  • Unstable congestive heart failure
  • History of spontaneous pneumothorax
  • Other medical conditions that interfere with participation in the study
  • Pregnant women

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Duke University Health System

    Durham, North Carolina, 27710

Other trials in United States

About this study

Official title: Non-invasive Positive Expiratory Pressure Mask (PEEP-Mask) for Tracheobronchomalacia Associated Cough

This study aims to determine if an expiratory resistance device that delivers non-invasive positive expiratory pressure (nPEP) will reduce or stop coughing, reduce airway resistance and improve quality of life in patients with tracheobronchomalacia (TBM) who are not candidates for tracheal stenting.

Read the detailed description

PROSPECTIVE:

Twenty subjects with chronic cough and TBM diagnosed by bronchoscopy or computed tomography (CT) scan will be recruited to enroll 12 participants. Comorbid conditions that can cause chronic cough, such as asthma, COPD, and GERD, must be treated if present, for subjects to qualify. At the pre-baseline visit (V0), after obtaining verbal informed consent, each subject will complete validated cough questionnaires to quantify their cough severity and cough-related QOL at baseline. The baseline visit (V1) will occur in-person approximately two weeks later, after a run-in period to minimize observation bias related to the cough questionnaires. Written consent will be performed at this visit. At V1, the cough questionnaires will be repeated and subjects' airway resistance and reactance will be measured with impulse oscillometry (IOS). A study physician will perform a physical exam and determine eligibility. Eligible subjects will then be given the nPEP device by the study team and instructed on its use. Approximately four to six weeks after device delivery, at the follow-up visit (V3), cough questionnaires and IOS will be repeated and they will be asked for feedback regarding device design and user experience. Subjects may then be entered into a cohort for up to six additional months, during which there will be no study visits or procedures, but subjects may be contacted by investigators for additional narrative feedback on the device and its use.

Study subjects will be given an nPEP device to use for four to six weeks. During this time participants will be asked to remain on their current medical regimen and not to make any dose changes or add new drugs, unless indicated by their primary care provider. Impulse oscillometry will be measured at V1 and 4-6 weeks later at V3 to assess effect of the nPEP device on airway physiology. A lung CT scan will be performed at V2.

RETROSPECTIVE:

This device was tried on two individuals and it was initiative and was beneficial. Many patients are not candidates for tracheobronchoplasty itself due to medical comorbidities, prefer to avoid the associated risks, or are not candidates for the required tracheal stenting due to trachea size or anatomy. These patients are left without a viable therapeutic option for their severe cough.

Continuous positive airway pressure (CPAP) devices have been reported to stop or prevent cough in TBM, presumably through pneumatic stenting the large airways to maintain their patency during exhalation. CPAP devices, however, are not labeled for this indication and their functional utility is very limited given size of the device, need for a power source, and multiple steps to don the equipment that are not easily completed while actively and uncontrollably coughing.

The physicians aimed to provide positive airway pressure at a low cost and through readily accessible means, in order to abort coughing paroxysms in patients who were not candidates for tracheal stenting and did not have access to commercial CPAP devices. Patients at Duke University Hospital referred to the Interventional Pulmonary service for evaluation of severe, debilitating TBM-related cough and possible tracheal stenting, but who were not candidates for tracheal stenting given their airway anatomy, were given positive end expiratory pressure (PEEP) masks assembled using existing hospital supplies. Specifically, a standard, adjustable (5-20 cm H2O) positive end expiratory pressure (PEEP) valve manufactured for attachment to a manual resuscitation (commonly known as bag-valve-mask) device was attached directly to a flexible face mask, also from a manual resuscitation device. Patients were instructed by their physicians how to use the PEEP masks. The patients used the PEEP mask immediately during their clinical encounter and were given a mask to take home. (The device was created by fellow, Lindsay Boole.)

This was a limited intervention for a very small number of patients (two), specifically identified as being referred to Duke Interventional Pulmonary service with severe cough related to TBM, but with anatomy that ruled them out as candidates for tracheal stenting. There were no formal data collected and no separate follow-up for the purpose of this project (though patients had ongoing clinical follow-up per standard of care). The patients' subjective improvement with the masks was submitted as a case report abstract and poster at the American College of Chest Physician meeting in 2017.

Other physicians asked Dr. Boole about the mask and if it could be used for their patients. Therefore, the investigators would like to request a retrospective review of all patients that used the PEEP mask between January 1, 2009 and August 20, 2019 to be included in this pilot study. Approximately 15 records will be reviewed.

Being tested
nPEP (non-invasive positive expiratory pressure) mask
Keywords
tracheobronchomalacia, TBM, cough
Medical subject headings
Tracheobronchomalacia, Cough

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • nPEP (non-invasive positive expiratory pressure) maskDevice

    Positive end expiratory pressure (PEEP) mask

Study groups in NCT04169282
Study groupRoleWhat they receive
nPEP RecipientsExperimentalSingle-patient, adjustable expiratory resistance device that provides positive pressure (5 to 20 cm H2O) during expiration
Receives: Device: nPEP (non-invasive positive expiratory pressure) mask

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS)

    The primary objective is to determine if use of the nPEP device will change cough severity. Responses to the Cough VAS range from 0-100 mm, with higher scores corresponding to worse outcomes.

    Measured: Baseline, two weeks

  2. Change in Quality of Life as Measured by the Cough-Specific Quality-of-Life Questionnaire (CQLQ)

    The CQLQ score ranges from 28 to 112, with higher scores corresponding to worse outcomes.

    Measured: Baseline, two weeks

  3. Change in Quality of Life as Measured by the Leicester Cough Questionnaire (LCQ)

    The LCQ score ranges from 19 to 133, with lower scores corresponding to worse outcomes.

    Measured: Baseline, two weeks

Secondary outcomes (1)
  1. Proximal Airway Reactance at 5 Hz (X5) as Assessed by Impulse Oscillometry

    The secondary objective is to determine if use of the nPEP device changes airway physiology, specifically proximal airway reactance, as assessed by impulse oscillometry. Reactance at 5 Hz (X5) relates to the physical properties of the lung parenchyma and its ability to expand and facilitate alveolar filling. A more negative X5 value indicates less elasticity of the lung.

    Measured: Baseline, two weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2019
  2. Study start30 Aug 2021
  3. Primary completion15 Aug 2022
  4. Study completion15 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04169282
Sponsor's protocol ID
Pro00102498
Status last verified
Sep 2023
First submitted
14 Nov 2019
Last updated
28 Sep 2023
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing nPEP (non-invasive positive expiratory pressure) mask in people with Tracheobronchomalacia, run by Duke University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Sep 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Cough Severity as Measured by the Cough Visual Analog Scale (VAS) (time frame: Baseline, two weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in